Allergen Immunotherapy in the Era of SARS-CoV-2

Compalati, Enrico; Erlewyn-Lajeunesse, Michel; Ali, Farhana; Fernández, Pérez; Núñez, Ignacio García; Frati, F; Mistrello, G.

doi:10.18176/jiaci.0568

Cited by 8 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 For AIT initiation, 27% of SCIT prescribers used SLIT more frequently, a trend that remained stable during the post peak phase. Several authors 10,11 suggested that SLIT might be more appropriate during the pandemic because of the possibility of home-based administration and of a better safety profile, thus minimizing visits to healthcare facilities.…”

Section: Descriptive Information Was Analysed and Compared Withmentioning

confidence: 99%

Real‐life report of allergen immunotherapy management during the COVID‐19 outbreak in France and Spain

Río

Caimmi

Rico³

et al. 2021

Clin Experimental Allergy

View full text Add to dashboard Cite

Section: Descriptive Information Was Analysed and Compared Withmentioning

confidence: 99%

Real‐life report of allergen immunotherapy management during the COVID‐19 outbreak in France and Spain

Río

Caimmi

Rico³

et al. 2021

Clin Experimental Allergy

View full text Add to dashboard Cite

“…Increasingly used over the last two decades as an alternative to subcutaneous immunotherapy, SLIT has been demonstrated to be efficacious in the treatment of the allergic patient [14]. Since SLIT enjoys an improved safety profile compared to SCIT, with the risk of severe systemic reaction quite low, it may be reasonable to convert SCIT patients to SLIT on a permanent basis so as to avoid disruption to immunotherapy [15]. At minimum, SLIT is a safe and reasonable tool in the allergist's armamentarium, particularly in the face of a pandemic with perhaps more limited access to hospital and clinic sites.…”

Section: Resuming Allergy Immunotherapymentioning

confidence: 99%

Allergy and Immunotherapy During the Pandemic

Davis

2022

Curr Otorhinolaryngol Rep

View full text Add to dashboard Cite

Purpose of Review To summarize and review recent literature on the role of allergen immunotherapy in the setting of a worldwide pandemic. Recent Findings At the start of the SARS-CoV-2 pandemic, most elective ambulatory patient care services, including allergen immunotherapy, were suspended. Now with medical practices reopening, allergists must establish plans and protocols for resuming care of allergy patients, including strategies for restarting allergen immunotherapy. While there are no published evidence-based protocols for resuming allergen immunotherapy, limited scientific data and expert opinion suggest that the major factor in dose adjustment is the time elapsed from the last dose. Summary Resuming outpatient allergy services in the setting of the COVID-19 pandemic poses many challenges to the practitioner. Allergy specialists are now faced with developing prudent and evidence-based strategies for safely resuming allergen immunotherapy, while also maintaining a safe environment for staff and patients.

show abstract

“…AIT can be continued in SARS-CoV-2 negative confirmed patients but with a prolonged injection interval 160 . Switching from subcutaneous to sublingual immunotherapy may be considered for AIT during COVID-19 161 . Skin manifestations of COVID-19 may be similar to other viral infections and drug hypersensitivity reactions (DHRs) 162,163 .…”

Section: Management Of Allergic Diseases During the Covid-19 Pandemicmentioning

confidence: 99%

Recent developments in the immunopathology of COVID-19

Gao

Zhang

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of COVID-19 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4 and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) has been identified as an important cause of death of children with COVID-19. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. Atopic diseases, such as allergic asthma and rhinitis, have been shown to be associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, EAACI developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging SARS-CoV-2 variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID.

show abstract

Allergen Immunotherapy in the Era of SARS-CoV-2

Abstract: Despite the challenges of the SARS-CoV-2 pandemic, seasonal allergies and asthma require

Cited by 8 publications

References 9 publications

Real‐life report of allergen immunotherapy management during the COVID‐19 outbreak in France and Spain

Real‐life report of allergen immunotherapy management during the COVID‐19 outbreak in France and Spain

Allergy and Immunotherapy During the Pandemic

Recent developments in the immunopathology of COVID-19

Contact Info

Product

Resources

About